Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Fondazione Toscana Gabriele Monasterio
Sponsor

Fondazione Toscana Gabriele Monasterio

Italy Via Trieste 41, 56126 Pisa, Italy

About the sponsor

Research activity centres on ATTR cardiac amyloidosis and AL cardiac amyloidosis, with a strong focus on PET/CT approaches for identifying cardiac amyloid deposits and distinguishing diagnostic pathways.

  • 18F-flutemetamol tracer evaluation
  • 18F-florbetaben PET/CT diagnostic assessment
  • Non-invasive diagnosis of AL-CA

The sponsor’s work in this area is directed toward improving the recognition of amyloid involvement in the heart and supporting clearer diagnostic classification across inherited and wild-type disease.

About Specializations

Fondazione Toscana Gabriele Monasterio runs clinical trials in conditions such as Cardiac amyloidosis, Atrial fibrillation, Acquired ATTR amyloidosis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Cardiac amyloidosis

Recruiting

Study to Diagnose Cardiac Amyloidosis in Patients with Monoclonal Component Using Florbetaben (18F) PET-CT

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Atrial fibrillation

Recruiting

Study Comparing Single and Dual Antiplatelet Therapy with Clopidogrel and Acetylsalicylic Acid for Patients with Atrial Fibrillation Undergoing Left Atrial Appendage Closure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Cardiac amyloidosis+1

Recruiting

Study on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Cardiac amyloidosis

Not recruiting

Study on the Use of Flutemetamol (18F) for Diagnosing Cardiac Amyloidosis in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Flutemetamol (18F)
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.